Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
docetaxel (taxotere) (1 trial)
naptumomab estafenatox (2 trials)
obinutuzumab (gazyva) (1 trial)
durvalumab (imfinzi) (1 trial)
Carcinoma, Hepatocellular (Phase 1)
Carcinoma, Ovarian Epithelial (Phase 1)
Endometrial Neoplasms (Phase 1)
Kidney Neoplasms (Phase 1)
Mesothelioma (Phase 1)
Trials (2 total)
Trial APIs (4 total)